BEST UNLIMITED TURBO LONG CERTIFICATE - INCYTE CO. | Market Closed - Euronext Paris 12:30:01 2024-05-10 EDT | ||
| 1.175 EUR | 0.00% |
|
| Current month | +14.35% | ||
| 1 month | -13.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
INCYTE CORPORATION
Latest news about INCYTE CORPORATION
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 1.195 | +1.70% | 24 |
| 24-05-09 | 1.175 | -4.08% | 36 |
| 24-05-08 | 1.225 | -6.13% | 29 |
| 24-05-07 | 1.305 | +3.16% | 25 |
| 24-05-06 | 1.265 | +6.75% | 29 |
Real-time Euronext Paris
Last update May 10, 2024 at 12:30 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | INCYTE CORPORATION |
| Issuer | 
Société Générale
|
| Q852S | |
| ISIN | DE000SU634G8 |
| Date issued | 2024-01-18 |
| Strike | 41.25 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.03 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.115 € |
|---|---|
| Lowest since issue | 0.94 € |
Company Profile
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
-
Consensus: Incyte Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
53.06
USD
Average target price
73.35
USD
Spread / Average Target
+38.24%
- Stock Market
- Certificates
- Q852S Certificat
